CD19 CAR T / Nationwide Children's - LARVOL DELTA

Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Nationwide Children's Hospital | Trial completion date: Dec 2027 ➔ Dec 2035 | Trial primary completion date: Dec 2026 ➔ Dec 2030

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • CD19

Infection after CD19 chimeric antigen receptor T cell therapy for large B cell lymphoma: Real-world analysis from CIBMTR. (PubMed, Blood Adv) - "The current study analyzed the natural history, risk factors, and outcomes of infection in 3350 R/R LBCL patients receiving commercial CD19 CAR T-cell (n=2804 axicabtagene ciloleucel, n=546 tisagenlecleucel) from December 2017 to June 2022. In conclusion, study results show a significant incidence of infection and IRM in patients with R/R LBCL treated with CD19 CAR T-cell. Furthermore, results identify patients at heightened risk for infection, offering insights to guide potential interventions aimed at mitigating infection and improving patient outcomes after CAR T-cell therapy."

Journal • Real-world evidence • B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Design of the First Clinical Trial of AAV Gene Therapy in Immuno-Oncology (SENTRY-ALL): A Single Dose CD3/CD19 Bi-Specific T-Cell Engager for the Treatment of CD19+ B-Cell Acute Lymphoblastic Leukemia (ASGCT 2025) - P1/2 | "VNX-101 is an investigational adeno-associated virus (AAV) gene therapy developed to express a secreted anti-CD19/anti-CD3 scFv diabody (termed GP101)...Prior blinatumomab and/or CD19 CAR T-cell treatment is allowed...This trial aims to provide the first clinical experience in the use of AAV gene therapy as a new paradigm for cancer immunotherapy. Disease Focus of Abstract:Cancer Hematologic"

Clinical • Gene therapy • Immuno-oncology • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Gene Therapies • Hematological Malignancies • Leukemia • Lymphoma • Oncology